Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.626 EUR 4.56% Market Closed
Market Cap: 170.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

P/E
Price to Earnings

-5.1
Current
-4.2
Median
21.6
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-5.1
=
Market Cap
171.9m EUR
/
Net Income
-33.5m EUR
All Countries
Close
Market Cap P/E
FR
Nanobiotix SA
PAR:NANO
171.9m EUR -5.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -172 725.2
US
Abbvie Inc
NYSE:ABBV
374.1B USD 88.3
US
Amgen Inc
NASDAQ:AMGN
168.2B USD 41.2
US
Gilead Sciences Inc
NASDAQ:GILD
131.1B USD 272.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
130.4B USD -244.7
US
Epizyme Inc
F:EPE
94.1B EUR -494.7
AU
CSL Ltd
ASX:CSL
123.6B AUD 28.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73B USD 16.6
US
Seagen Inc
F:SGT
39.3B EUR -57.3
NL
argenx SE
XBRU:ARGX
34B EUR 44.6
Earnings Growth PEG
FR
Nanobiotix SA
PAR:NANO
Average P/E: 82
Negative Multiple: -5.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 725.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.3
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
272.6
185%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -244.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.7 N/A N/A
AU
CSL Ltd
ASX:CSL
28.6
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.3 N/A N/A
NL
argenx SE
XBRU:ARGX
44.6
19%
2.3

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-3.4
2-Years Forward
P/E
-3.5
3-Years Forward
P/E
-6